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A B S T R A C T
Background: Interleukin (IL)-17A is proinflammatory cytokine produced by Th17 cells, which play key, but
sometimes inconsistent role in autoimmunity and cancer. Polymorphic variants in IL-17A gene were differen-
tially associated with susceptibility to cancer, including colorectal cancer (CRC).
Aim: We investigated the association between six IL-17A gene variants (rs3819024, rs2275913, rs3819025,
rs10484879, rs7747909, and rs3748067) with CRC susceptibility in Tunisians.
Subjects and Methods: Retrospective case-control study. Study subjects comprised 293 patients with CRC, and
268 age-, gender-, and BMI-matched healthy controls. IL-17A genotyping was done by real-time PCR, with
defined clusters.
Results: Of the seven tested IL-17A tag-SNPs, minor allele frequency (MAF) of rs10484879 was significantly
higher in CRC patients than control subjects. Heterozygous rs10484879 [OR (95% CI)= 2.63 (1.64–4.21)] was
associated with higher risk, while carriage of heterozygous rs3748067 genotype was associated with reduced
risk of CRC [OR (95% CI)= 0.56 (0.37–0.84)], respectively. Carriage of rs10484879 minor allele correlated with
positive family history of CRC and other cancers (P=0.002), CRC staging (P=0.044), CRC treatment
(P=0.038), and with chemo body reaction (P=0.001). Of the 7 IL-17A variants, 4 were in linkage dis-
equilibrium, hence allowing for construction of 4-locus haplotypes. Varied linkage disequilibrium (LD) was
noted between the even tested IL-17A variants, and further analysis was limited to only 4-locus (rs3819024-
rs2275913- rs10484879-rs7747909). Haploview analysis identified the 4-locus IL-17A haplotypes AGTG
(P < 0.011), and GATG (P=0.036) to be positively associated with CRC, after controlling key covariates.
Conclusion: IL-17A rs10484879 SNP, and IL-17A haplotypes AGGTG and GAGTG constitute independent factors
of CRC susceptibility. We propose that IL-17A may be a target for future CRC immunotherapy.
1. Introduction
Colorectal cancer (CRC) is a malignant tumor of the large intestine
with rising frequency worldwide, and a major global public health
concern [1,2]. With approximately 608,000 deaths attributed to it
worldwide, CRC accounts for 8% of all cancer deaths, and is numeri-
cally the fourth common cause of cancer deaths [2]. The prevalence of
CRC is estimated at 6.3/100,000 per year in Tunisia [3], with
comparable incidence in males and females. The diagnosis CRC is made
on clinical (abdominal examination, palpation of the lymph nodes, and
colonoscopic examination of the interior colon and rectum) [4,5], and
laboratory findings (blood in the stool, ACE, CA19-9) [6]. While its
exact causes are still poorly understood, several modifiable (lifestyle,
inflammatory diseases, microbiota imbalance) [7–9], and non-modifi-
able factors contribute to CRC pathogenesis. The latter include ethic/
racial background, and polymorphic variants in inflammatory
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mediators, including cytokine [10–12].
Interleukin (IL)17 is a 155 amino acids pro-inflammatory cytokine,
and is produced by Th17 cells [13,14]. IL-17 belongs to family of six
homologous proteins, designated IL-17A through IL-17F [15,16], of
which IL-17A and IL-17F are the most investigated. Several factors
trigger the release of IL-17, including IL-6 and TGF-β, which stimulate
the differentiation of CD4+ T cells into IL-17-producing Th17 cells
[13,14,17]. Functionally, IL-17 induces the production of pro-in-
flammatory chemokines and cytokines, including IL-1, IL-6, TNF-α, G-
CFS. These bind high-affinity receptors on epithelial cells, endothelial
cells, fibroblasts and other immune cells, and trigger a local in-
flammatory response [13,18]. IL-17 production is tightly regulated, and
over-production of IL-17 induces a state of low-grade chronic in-
flammation [18], associated with a myriad of pathologies, including
allergies, celiac disease, and cancers, including colorectal cancer
[15,19–21].
Recently, it was suggested that elevated levels of IL-17A-producing
cells are associated with poor prognosis of CRC, principally resulting
from increased VEGFA expression [22–24]. IL-17A gene is located on
chromosome 6 (6p12.2), and contains 3 exons and 2 introns spanning
4252 bp. Several polymorphic variants in IL-17A gene were reported, of
which some were functional. A recent Tunisian study involving 102
CRC patients demonstrated positive association of rs2275913 minor (A)
allele with increased susceptibility to CRC, and with CRC-associated
features, such as tumor localization, tumor differentiation, and TNM
stage [10]. A similar study on Chinese patients confirmed the positive
association of rs2275913 with increased susceptibility to colorectal
[19] and other cancers [15,20,24]. As other variants in IL-17A may be
associated with CRC susceptibility, here we investigated the association
of six polymorphic variants in IL-17A gene with the presence of CRC
and accompanying features, in Tunisian population comprising of 294
patients with CRC, and 263 healthy cancer-free control subjects.
2. Subjects and Methods
2.1. Study subjects
This was a retrospective case-control study, performed at the out-
patient oncology service of Saleh Azeiz Hospital (Tunis, Tunisia).
Between February 2014 to October 2016, 294 subjects with CRC (mean
age 58.8 ± 14.4 years), and 263 cancer-free control women (mean age
57.2 ± 18.1 years), comprising university and hospital employees, or
volunteer women, were recruited into the study. None of control sub-
jects reported personal or family history of CRC, and were matched to
CRC cases according to self-declared ethnic origin. CRC assessment was
based on clinical examination, colonoscopy, and histopathology on
isolated biopsies; all cases had these tests done.
Demographic and clinical information were collected for CRC pa-
tients from clinical records, and by personal interview using a unified
questionnaire by referring physician. These included gender, age at
study entry and at CRC diagnosis, anemia, hypertension, and smoking
history. Detailed histological assessment (differentiation status), tumor
localization (rectum or colon/sigmoid), and treatment were recorded
for all patients. The study was done according to Helsinki II declaration,
and approved by the research & ethics committees of Saleh Azeiz
Hospital and El Manar University in Tunis; all participants provided
informed consent.
2.2. IL-17A genotyping
We identified six single nucleotide polymorphisms (SNP) in IL-17A
gene with a minor allele frequency (MAF) ≥5%, which were reported
in the literature with clinical relevance using NCBI Entrez Gene SNP
Geneview. IL-17A genotyping was done by VIC- and FAM-labelled al-
lelic discrimination method, using assay-on-demand TaqMan assays
ordered from Applied Biosystems (Foster City, NJ). The reaction was
performed in 6 μl volume on StepOne Plus real-time PCR system, ac-
cording to manufacturer’s instructions (Applied Biosystems). Replicate
blinded quality control samples were included to check for the re-
producibility of the genotyping results; concordance was> 99%. The
average successful genotyping rate for each sample and SNP was 97.9%.
2.3. Statistical analysis
Statistical analysis was performed by SPSS version 23 (IBM;
Armonk, NY). Continuous data were presented as mean ± SD, and
categorical variables were listed as percent of total. Student’s t-test, and
Pearson χ2 test was used for assessment of differences in means and
inter–group significance, respectively. Power calculation was done by
Genetic Power Calculator (http://pngu.mgh.harvard.edu/~purcell/cgi-
bin/cc2k.cgi). The parameters used were 294 CRC patients and 263
control subjects, minor allele frequency (MAF) for the tested variants in
CRC patients, estimated prevalence of CRC in Tunisia, along with
genotypic relative risk for heterozygote (1/2) and minor allele homo-
zygous (2/2). Assuming these parameters, the overall average power
was calculated at 69.1%.
Haploview 4.2 (www.broad.mit.edu/mpg/ haploview) was used in
testing Hardy–Weinberg equilibrium (HWE). Frequencies for
Caucasians (CEU), African Americans of the American Southwest
(ASW) and Yoruban in Ibadan, Nigeria (YRI) were obtained from
HapMap release #28, for comparison of allele frequencies obtained in
this study to those previously reported. All analyses were performed
under the assumption of additive genetic effect. Haploview 4.2 was
used to check linkage disequilibrium (LD) between SNPs, and haplotype
patterns. IL-17A haplotypes was reconstructed by the expectation
maximization method. Of the possible 64 IL-17A haplotypes, 9 were
found to be common (frequency>1.5%), and were included in further
analysis. Taking control group as reference, logistic regression analysis
was used for determining odds ratios (OR) and 95% confidence inter-
vals (95%CI) associated with CRC risk. Statistical significance set at
P < 0.05.
3. Results
3.1. Study subjects
The demographics and clinical characteristics of study participants
Table 1
Characteristics of study participants.
Parameter Cases Controls Pa
Gender (M:F)b 139 (47.4): 154
(52.6)
126 (47.0): 142
(53.0)
0.933
Age (yr)c 58.8 ± 14.4 57.2 ± 18.1 0.247
BMI (kg/m2)c 25.1 ± 5.0 25.0 ± 2.8 0.807
Anemiab 59 (20.1) 30 (11.2) 0.005
Hypertensionb 67 (22.9) 45 (20.0) 0.453
Smokingb 102 (34.8) 70 (26.1) 0.028
Tumor localizationb:
rectum
106 (38.0) NA NA
Colon and Sigmoid 173 (62.0) NA NA
Differentiationb: Poor 88 (31.7) NA NA
Moderate 119 (42.8) NA NA
Treatmentb: Chemotherapy 199 (74.5) NA NA
Radiotherapy 2 (0.7) NA NA
Chemotherapy
+radiotherapy
64 (24.0) NA NA
Surgery 2 (0.7) NA NA
Mixed 31 10.4) NA NA
a Student’s t-test (continuous variables), Pearson’s chi square test (catego-
rical variables).
b Mean± SD.
c Number of subjects (percent total).
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are shown in Table 1. Mean age at entry of study, gender, body-mass
index (BMI), and hypertension were comparable between CRC patients
and control subjects. Significant differences between CRC cases and
controls were noted in the number of smokers (P=0.028), and in-
cidence of anemia (P=0.005). Accordingly, we selected these as the
main covariates that we controlled for in subsequent analysis. Most CRC
cases involved the colon and sigmoid (62%), and most were treated
with chemotherapy (74.5%).
3.2. Association studies
The genotype distributions of the tested IL-17A variants were in
HWE among study subjects (Table 2). MAF of the tested IL-17A variants
in CRC patients and control subjects are presented in Table 2. Of the IL-
Table 2
Distribution of IL-17A alleles in colorectal cancer cases and control subjects.
SNP Positiona Alleles Cases MAF Controls MAF HWE χ2 P aORb (95% CI) Power %
rs3819024 52185988 A:G 131 (0.223) 117 (0.219) 0.43 0.02 0.887 1.02 (0.77–1.36) 54.6
rs2275913 52186235 G:A 107 (0.183) 77 (0.145) 0.28 2.90 0.089 1.32 (0.96–1.82) 73.1
rs3819025 52186476 G:A 95 (0.162) 83 (0.155) 0.10 0.10 0.758 1.05 (0.76–1.45) 57.3
rs10484879 52187159 C:T 98 (0.167) 52 (0.097) 0.35 11.76 6.00× 10−4 1.86 (1.30–2.67) 99.6
rs7747909 52189451 G:A 92 (0.156) 101 (0.188) 0.10 2.02 0.156 0.80 (0.59–1.09) 64.8
rs3804513 52188399 A:T 45 (0.08) 28 (0.07) 0.08 0.16 0.689 1.11 (0.68–1.80) 71.2
rs3748067 52190541 G:A 92 (0.156) 100 (0.187) 0.07 1.79 0.180 0.81 (0.59–1.10) 62.8
MAF, Minor allele frequency; HWE, Hardy-Weinberg Equilibrium.
a Location on chromosome based on dbSNP build 125.
b aOR= adjusted OR, adjusted for anemia and smoking.
Table 3
IL-17A Genotype frequencies.
1/1a 1/2a 2/2a
SNP Cases Controls P Cases Controls OR (95% CI) Cases Controls OR (95% CI)
rs3819024 177 (0.60)b 167 (0.63) 0.39 103 (0.35) 80 (0.30) 1.21 (0.85–1.74) 14 (0.05) 17 (0.06) 0.78 (0.37–1.63)
rs2275913 199 (0.68) 194 (0.74) 0.27 79 (0.27) 58 (0.22) 1.33 (0.90–1.97) 14 (0.05) 9 (0.03) 1.52 (0.64–3.59)
rs3819025 213 (0.72) 192 (0.72) 0.69 67 (0.23) 64 (0.24) 0.94 (0.64–1.40) 14 (0.05) 9 (0.03) 1.40 (0.59–3.31)
rs10484879 184 (0.67) 220 (0.83) < 0.001 84 (0.31) 39 (0.15) 2.58 (1.68–3.95) 7 (0.03) 6 (0.02) 1.39 (0.46–4.22)
rs7747909 211 (0.72) 182 (0.69) 0.17 74 (0.25) 66 (0.25) 0.97 (0.66–1.42) 9 (0.03) 17 (0.06) 0.46 (0.20–1.05)
rs3748067 213 (0.72) 192 (0.72) 0.69 67 (0.23) 64 (0.24) 0.94 (0.64–1.40) 14 (0.05) 9 (0.03) 1.40 (0.59–3.31)
Boldface indicates statistically significant differences.
a Genotypes were coded as per “1″=major allele, “2”=minor allele.
b Number of subjects (frequency).
Table 4
Effects of IL-17A SNP genotypes on the risk of CRC according to the different genetic models.
Codominant Model Dominant Model Recessive Model Log additive
Genotype P-value a OR (5% CI)a P-value a OR (5% CI) P-value a OR (5% CI) P-value a OR (5% CI)
rs2275913 G/G 0.29 1.00 (Reference) G/G vs. G/A+A/A G/G+G/A vs. A/A 0.12 1.30 (0.93–1.81)
G/A 1.36 (0.89–2.09) 0.12 1.38 (0.92–2.07) 0.50 1.37 (0.54–3.46)
A/A 1.48 (0.58–3.77)
rs3819024 A/A 0.52 1.00 (Reference) A/A vs. A/G+G/G A/A+A/G vs. G/G 0.93 1.01 (0.75–1.37)
A/G 1.17 (0.79–1.73) 0.62 1.10 (0.76–1.59) 0.41 0.72 (0.33–1.56)
G/G 0.76 (0.34–1.67)
rs7747909 G/G 0.20 1.00 (Reference) G/G vs. G/A+A/A G/G+G/A vs. A/A 0.28 0.84 (0.61–1.15)
G/A 1.02 (0.67–1.56) 0.60 0.90 (0.61–1.34) 0.073 0.46 (0.19–1.09)
A/A 0.46 (0.19–1.10)
rs3819025 G/G 0.48 1.00 (Reference) G/G vs. G/A+A/A G/G+G/A vs. A/A 0.93 1.01 (0.73–1.41)
G/A 0.86 (0.57–1.31) 0.74 0.94 (0.63–1.39) 0.32 1.62 (0.61–4.30)
A/A 1.56 (0.59–4.16)
rs3748067 G/G 0.003 1.00 (Reference) G/G vs. G/A+A/A G/G+G/A vs. A/A 0.33 0.85 (0.61–1.18)
G/A 0.56 (0.37–0.84) 0.04 0.67 (0.45–0.99) 0.04 2.83 (0.93–8.60)
A/A 2.42 (0.79–7.40)
rs3804513 A/A 0.13 1.00 (Reference) A/A vs. A/T+T/T A/A+A/T vs. T/T 0.74 1.07 (0.71–1.62)
A/T 0.64 (0.33–1.23) 0.71 0.90 (0.51–1.58) 0.13 2.27 (0.73–7.08)
T/T 2.19 (0.70–6.83)
rs10484879 C/C <0.001 1.00 (Reference) G/G vs. G/A+A/A G/G+G/A vs. A/A <0.001 1.99 (1.34–2.95)
C/T 2.63 (1.64–4.21) < 0.001 2.43 (1.55–3.79) 0.97 1.02 (0.32–3.27)
T/T 1.27 (0.40–4.08)
Boldface indicates statistically significant differences.
a Models controlled for gender, BMI, anemia, and smoking.
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17A SNPs analyzed, higher MAF of rs10484879 (P < 0.001) was seen
in CRC cases than in control subjects. MAF of the remaining five tested
variants were comparable between CRC patients and control subjects.
Carriage of rs10484879 minor allele correlated with positive family
history of CRC and other cancers (P=0.002), CRC staging (P=0.044),
CRC treatment (P=0.038), and with chemo body reaction
(P=0.001).
The distribution of IL-17A genotypes in CRC patients and control
subjects are listed in Table 3. Significant differences in the distribution
of IL-17A rs10484879 (P < 0.001) genotypes were seen between CRC
cases compared to control subjects. The association of IL-17A
rs10484879 with CRC persisted after controlling for gender, BMI, an-
emia, and smoking (P=0.003). The risk of CRC associated with a
specific IL-17A genotype was further confirmed by testing the effect of
gender, BMI, anemia, and smoking as confounders. Results from Table 4
confirmed the association of rs10484879 with CRC under the codomi-
nant (aP < 0.001), dominant (aP < 0.001), and log-additive (aP <
0.001) genetic models. In addition, rs3748067 was found to be
associated with CRC under the codominant (P=0.003) and dominant
(P=0.04) only. The association of both rs10484879 and rs3748067
with CRC was seen only in heterozygous carriers (Table 4)
3.3. Haploview analysis
Varied LD was noted between the even tested IL-17A variants, and
further analysis was limited to only 4-locus (rs3819024-rs2275913-
rs10484879-rs7747909) (Fig. 1). Among these, common haplotype
(> 2% of total) seen in 7 of the possible 16 haplotypes. Haploview
analysis identified the 4-locus IL-17A haplotypes AGTG (P < 0.011),
and GATG (P=0.036) to be positively associated with CRC (Table 5).
4. Discussion
Several studies highlighted the role of the immune system in gas-
trointestinal pathologies [25,26], including CRC [22,23,27]. In this
regard, it was shown that a state of dysregulated anti-inflammatory and
pro-inflammatory cytokine balance accompany the pathogenesis of
CRC. Despite the central role of IL-17 in cancer pathogenesis [28–30],
including CRC [19,22], to our knowledge, few studies addressed the
involvement of IL-17 in CRC in Tunisia, often with inconclusive find-
ings. In this context, we analyzed the association between IL-17A
rs3819024, rs2275913, rs3819025, rs10484879, rs7747909, and
rs3748067 gene variants and the occurrence of CRC. Results obtained
demonstrated positive association of IL-17A rs10484879 SNP and AGTG
and GATG haplotypes with CRC. This is the first study that identifies the
positive association of these haplotypes with increased risk of CRC.
Heightened IL-17 expression was documented for several tumors,
including hepatocellular carcinoma [21], cervical cancer [31], lung
cancer [32], bladder cancer [20], colorectal cancer [22], and others
[19]. According to these studies, IL-17 facilitates tumor progression by
inducing angiogenesis. For example, increased intra-tumor accumula-
tion of IL-17A-producing cells was associated with an increased vas-
culogenesis in hepatocellular carcinoma [33], and increased intra-
tumor Tc17 cell activity promoted vasculogenesis in cervical cancer
[31]. Furthermore, elevated levels of IL-17A-producing cells was asso-
ciated with increased lymphangiogenesis in lung cancer [34].
There is growing evidence that IL-17 can promote CRC progression,
via an incompletely understood mechanism. It was shown that in-
creased abundance of IL-17A-producing cells, and heightened expres-
sion of IL-17 facilitate CRC progression of by inducing a state of en-
hanced angiogenesis [19,22]. It was also suggested that CRC
progression resulted from altered activity of Th17 cells, and/or im-
balance of Th1/Th2 ratio [35]. This was highlighted by the findings
that functional Th1 cells and Th17 cells clusters produce opposite ef-
fects on CRC patient survival, whereby strong Th17 expression was
associated with poor cancer prognosis, when compared to strong Th1
profile, which was associated with prolonged and sustained CRC-free
survival [23,35]. In contrast, Th2 did not predict prognosis [23].
Recruitment of CRC patients was based on clinico-pathological
findings, which were obtained irrespective of family history, from
clinical records of patients with colon and rectal cancer. On the other
hand, control subjects were blood donors, or volunteers from the
community, with no personal or CRC family history (CC or RC). Both
modifiable (BMI, smoking) and non-modifiable (age, gender, ethnic
background) factors contribute to CRC development. This was high-
lighted by the link of obesity with increased risk of CRC [1,8,9], and by
the association of weight gains during adulthood with heightened risk
of colon cancer in men [8]. Accordingly, the contribution of key cov-
ariates to the association of IL-17A variants and haplotypes and overall
CRC risk was addressed throughout the study.
In this retrospective case-control study, we investigated the asso-
ciation between CRC risk and the six IL-17A gene variants rs3819024,
rs2275913, rs3819025, rs10484879, rs7747909, and rs3748067. IL-
17A gene is located on chromosome 6, position 6p12.2, and contains
Fig. 1. Linkage disequilibrium (LD) map of IL-17A SNPs genotyped by
Haploview. The positions of the SNPs (Build 37.3) are displayed above the
Haploview output. The relative LD between any pair of SNPs is indicated by the
color scheme, which represents LD relationships, which is based on D’values
(normalized linkage disequilibrium measure or D) multiplied by 100; D’ is
calculated as D divided by the theoretical maximum for the observed allele
frequencies. Values approaching zero indicate no LD, and those approaching
100 indicate complete LD. The square colored red represent varying degrees of
LD < 1 and LOD (logarithm of odds)> 2 scores; darker shades indicating
stronger LD.
Table 5
Haplotype frequencies across the IL-17A SNPs.a
Haplotypeb Frequency Case, Control frequencies χ2 P
A G C G 0.652 0.634, 0.679 2.081 0.149
G A T A 0.068 0.064, 0.074 0.393 0.531
G G C G 0.066 0.060, 0.076 0.999 0.318
A G C A 0.056 0.046, 0.072 2.915 0.088
A G T G 0.036 0.058, 0.004 19.871 8.28× 10−6
G A C G 0.034 0.038, 0.028 0.761 0.383
G A T G 0.020 0.028, 0.009 4.401 0.036
aIL-17A block contains rs3819024, rs2275913, rs10484879, rs7747909.
b Bold underlined indicate minor allele.
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857 polymorphic variants, distributed between near-gene (296), UTR
(163), exonic (102), and intronic (296) variants. Positive association
was seen between rs10484879 IL-17A gene variant, notably as hetero-
zygous, and CRC. MAF of rs10484879 established for healthy Tunisians
(9.7%), while comparable to the global MAF (10.9%), was markedly
lower than that established for European (24.94%) (www.ncbi.nlm.nih.
gov/projects/SNP/snp), but higher than the frequencies seen in Asians
(< 1.0%) and Africans (1.7%). This reflects the genetic makeup of
present-day Tunisians, who represent an admixture between original
African (Berber) origin and invading Caucasians/Europeans throughout
history. In contrast, none of the other genotypes was associated with
altered risk of CRC. TO the best of our knowledge, this study is the first
to confirm association between CRC and IL-17A rs10484879 gene
variant.
Earlier studies reveal an association between IL-17A rs2275913
variant and cancers other than CRC, such as breast cancer [24], gastric
cancer [15,16,21,36], bladder cancer [20], and cervical cancer [29,31].
A recent meta-analysis of 26 case-control studies, comprising 20 studies
on Asians and 6 studies on Caucasians, and involving 7872 cases,
confirmed that IL-17A rs2275913 (and IL-17F rs763780) polymorph-
isms is associated with increased risk for some (gastric, cervical, CRC),
but not all (hepatocellular carcinoma) cancer types [37]. It is note-
worthy that the association of rs2275913 with CRC was seen only under
dominant genetic model, and was more pronounced in Asians than
Caucasians [37]. This highlights the need for additional studies on re-
lated and distant populations aimed at establishing a role for the IL-17A
rs2275913 as a genetic marker of CRC, and possibly associated features.
In our hands, there was lack of association between rs2275913 and
CRC. This was in apparent disagreement with recent Tunisian [10], and
Iranian [12] studies, which suggested an association between
rs2275913 IL-17A gene variant and CRC. These apparent discrepancies
are attributed to ethnic differences [12], bias in diagnosing CRC, and
the study design. Furthermore, unlike our study which included 293
CRC patients, both studies of Omrani on Tunisians (102 CRC patients
and 139 controls), and Nemati on Southern Iranian (202 patients and
203 controls) were smaller in size, and with the magnitude of the as-
sociation obtained, this question the relevancy of the conclusions
reached.
In addition, haploview analysis demonstrated the association of
haplotypes AGTG and GATG with CRC. These were constructed based
on the LD pattern established, which necessitated removal of
rs3819025, rs3804513, and rs3748067 from the block, owing to ab-
sence of LD with remaining variants. Whereas previous studies identi-
fied select haplotypes associated with breast cancer [24], but not with
CRC [12]. Difference between our results and those of Nemati are likely
attributed to ethnic background (Iranian vs. Tunisian), sample size, and
experimental interpretation [12].
5. Conclusion
In conclusion, our study showed a positive association IL-17A
rs104284879, as well as AGTG and GATG haplotypes with CRC. Our
study has strengths. First, cases and controls were ethnically assimi-
lated, thus reducing the problems of genetic background differences.
Second, we used tag-SNPs, thus increasing the coverage of IL-17A gene.
However, our study had also limitations, namely the relatively limited
sample size (293 patients) which did not allow for subgroup analysis,
and did not provide for addressing cause-effect relationship, given its
retrospective case-control design. In addition, some possible sources of
heterogeneity, including selection of controls, and proper assessment of
the contribution of lifestyle/environmental factors, were not explored.
Follow-up studies on additional IL-17A SNPs, and populations of dif-
ferent ethnic origins are needed to confirm, or alternatively rule of the
association of IL-17A SNPs with altered risk of CRC.
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